OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ORBIA58

Orbia Advance Corporation SAB de CV

Commodity ChemicalsVerified

Orbia's capital structure is characterized by a high debt-to-equity ratio of 2.67, indicating significant leverage. The company's liquidity position is moderate, with a current ratio of 1.52, but its free cash flow is negative at -115 million USD, which may constrain its ability to fund operations without external financing. The company's return on equity is -21.41%, and its return on assets is -4.13%, both of which are below typical performance metrics for the industry. In terms of profitability, Orbia's net income is negative at -457 million USD, and its operating income is 370 million USD, which is lower than the industry median for commodity chemicals. The company's gross profit of 1.626 billion USD suggests some level of cost control, but the overall profitability is weak. The company's operating cash flow is 840 million USD, which is a positive sign, but it is not sufficient to cover capital expenditures of 405 million USD. Orbia's revenue is concentrated in the chemicals segment, with no disclosed geographic breakdown. The company's exposure to a single business line may increase its vulnerability to market fluctuations in the chemicals industry. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the company's capital expenditures suggest ongoing investment in its operations. The company faces several risk factors, including a high debt-to-equity ratio and negative free cash flow, which could lead to liquidity constraints. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. There are no recent events or filings that significantly impact the company's risk profile. Analyst estimates for Orbia are mixed, with a mean price target of 26.33 USD and a median price target of 25.00 USD. The mean recommendation is 2.50, indicating a slight bias towards a hold or buy rating. There is one strong-buy recommendation, six buy recommendations, and six hold recommendations.

30-day price · ORBIA+0.21 (+1.0%)
Low$20.29High$24.04Close$22.01As of25 May, 00:00 UTC
Profile
CompanyOrbia Advance Corporation SAB de CV
TickerORBIA.MX
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Orbia Advance Corporation SAB de CV is a chemicals company that produces commodity chemicals and generates revenue primarily through the sale of chemical products.

Classification. Orbia is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Orbia's capital structure is characterized by a high debt-to-equity ratio of 2.67, indicating significant leverage. The company's liquidity position is moderate, with a current ratio of 1.52, but its free cash flow is negative at -115 million USD, which may constrain its ability to fund operations without external financing. The company's return on equity is -21.41%, and its return on assets is -4.13%, both of which are below typical performance metrics for the industry. In terms of profitability, Orbia's net income is negative at -457 million USD, and its operating income is 370 million USD, which is lower than the industry median for commodity chemicals. The company's gross profit of 1.626 billion USD suggests some level of cost control, but the overall profitability is weak. The company's operating cash flow is 840 million USD, which is a positive sign, but it is not sufficient to cover capital expenditures of 405 million USD. Orbia's revenue is concentrated in the chemicals segment, with no disclosed geographic breakdown. The company's exposure to a single business line may increase its vulnerability to market fluctuations in the chemicals industry. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the company's capital expenditures suggest ongoing investment in its operations. The company faces several risk factors, including a high debt-to-equity ratio and negative free cash flow, which could lead to liquidity constraints. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. There are no recent events or filings that significantly impact the company's risk profile. Analyst estimates for Orbia are mixed, with a mean price target of 26.33 USD and a median price target of 25.00 USD. The mean recommendation is 2.50, indicating a slight bias towards a hold or buy rating. There is one strong-buy recommendation, six buy recommendations, and six hold recommendations.
Key takeaways
  • Orbia has a high debt-to-equity ratio of 2.67, indicating significant leverage.
  • The company's net income is negative at -457 million USD, and its operating income is 370 million USD, which is lower than the industry median for commodity chemicals.
  • Orbia's liquidity position is moderate, with a current ratio of 1.52, but its free cash flow is negative at -115 million USD.
  • The company's return on equity is -21.41%, and its return on assets is -4.13%, both of which are below typical performance metrics for the industry.
  • Analyst estimates for Orbia are mixed, with a mean price target of 26.33 USD and a median price target of 25.00 USD.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's gross profit margin is 21.33%, but the net margin is negative at -6.00%, indicating significant cost pressures and operational inefficiencies.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$7.62B
Gross profit$1.63B
Operating income$370.0M
Net income-$457.0M
R&D
SG&A
D&A
SBC
Operating cash flow$840.0M
CapEx-$405.0M
Free cash flow-$115.0M
Total assets$11.07B
Total liabilities$8.94B
Total equity$2.13B
Cash & equivalents$1.04B
Long-term debt$5.71B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.13B
Net cash-$4.67B
Current ratio1.5
Debt/Equity2.7
ROA-4.1%
ROE-21.4%
Cash conversion-1.8%
CapEx/Revenue-5.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricORBIAActivity
Op margin4.9%5.5% medp25 -0.0% · p75 10.8%below median
Net margin-6.0%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin21.3%20.5% medp25 12.4% · p75 29.7%above median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-5.3%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity267.0%37.1% medp25 10.3% · p75 82.0%top quartile
Observations
IR observations
Mean price target26.33 USD
Median price target25.00 USD
High price target48.00 USD
Low price target13.00 USD
Mean recommendation2.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count6.00
Hold count6.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.03 USD
Last actual EPS-0.23 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 21:55 UTC#4bb04baf
Market quoteclose USD 22.08 · shares 1.97B diluted
no public URL
2026-05-22 21:55 UTC#7406ade1
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:09 UTCJob: 47db833a